ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone41-22-552-3840
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees43
Next Earnings Date3/3/2020 (Estimated)
OptionableNot Optionable
Obseva (NASDAQ:OBSV) Frequently Asked Questions
What is Obseva's stock symbol?
Obseva trades on the NASDAQ under the ticker symbol "OBSV."
How were Obseva's earnings last quarter?
Obseva SA (NASDAQ:OBSV) issued its quarterly earnings results on Thursday, November, 7th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.82) by $0.19. View Obseva's Earnings History.
When is Obseva's next earnings date?
What price target have analysts set for OBSV?
4 Wall Street analysts have issued 1-year target prices for Obseva's stock. Their forecasts range from $4.00 to $44.00. On average, they expect Obseva's stock price to reach $28.67 in the next twelve months. This suggests a possible upside of 938.6% from the stock's current price. View Analyst Price Targets for Obseva.
What is the consensus analysts' recommendation for Obseva?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Obseva in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Obseva.
What are Wall Street analysts saying about Obseva stock?
Here are some recent quotes from research analysts about Obseva stock:
- 1. According to Zacks Investment Research, "ObsEva SA is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics for woman's reproductive health and pregnancy. ObsEva SA is headquartered in Geneva, Switzerland. " (11/9/2019)
- 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. Our risk-adjusted net present value (rNPV) approach ascribes $1.9B to linzagolix (formerly to nolasiban. We utilize an 85% probability of approval for linzagolix and 75% for nolasiban." (9/4/2019)
Has Obseva been receiving favorable news coverage?
Press coverage about OBSV stock has been trending very negative recently, according to InfoTrie. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Obseva earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Obseva.
Who are some of Obseva's key competitors?
Some companies that are related to Obseva include Intra-Cellular Therapies (ITCI), Myovant Sciences (MYOV), Catalyst Pharmaceuticals (CPRX), Progenics Pharmaceuticals (PGNX), Synthorx (THOR), BioDelivery Sciences International (BDSI), Homology Medicines (FIXX), ImmunoGen (IMGN), Aprea Therapeutics (APRE), Advanz Pharma (CXRXF), Urogen Pharma (URGN), Aurinia Pharmaceuticals (AUPH), Cytokinetics (CYTK), Akebia Therapeutics (AKBA) and Basilea Pharmaceutica (BPMUF).
What other stocks do shareholders of Obseva own?
Who are Obseva's key executives?
Obseva's management team includes the folowing people:
- Dr. Ernest Loumaye, Co-Founder, CEO & Director (Age 67)
- Mr. Timothy M. Adams, Chief Financial Officer (Age 59)
- Dr. Jean-Pierre Gotteland Ph.D., Chief Scientific Officer and Head of R&D (Age 54)
- Mr. Mario Vincent Corso, Sr. Director of Investor Relations
- Dr. Elke Bestel M.D., Chief Medical Officer & Head of Pharmacovigilance (Age 53)
When did Obseva IPO?
(OBSV) raised $98 million in an initial public offering on Thursday, January 26th 2017. The company issued 6,500,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO.
Who are Obseva's major shareholders?
Obseva's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Wedbush Securities Inc. (0.09%).
Which major investors are buying Obseva stock?
OBSV stock was bought by a variety of institutional investors in the last quarter, including Wedbush Securities Inc..
How do I buy shares of Obseva?
Shares of OBSV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Obseva's stock price today?
One share of OBSV stock can currently be purchased for approximately $2.76.
How big of a company is Obseva?
Obseva has a market capitalization of $125.52 million. The company earns $-76,720,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. Obseva employs 43 workers across the globe.View Additional Information About Obseva.
What is Obseva's official website?
How can I contact Obseva?
Obseva's mailing address is Chemin des Aulx 12 Plan-les-Ouates, Geneva V8, 1228. The company can be reached via phone at 41-22-552-3840 or via email at [email protected]
MarketBeat Community Rating for Obseva (NASDAQ OBSV)
MarketBeat's community ratings are surveys of what our community members think about Obseva and other stocks. Vote "Outperform" if you believe OBSV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OBSV will underperform the S&P 500 over the long term. You may vote once every thirty days.
